Eubiologics IPO Part 2 - Growth Potential & Appropriate Valuation Level
* In Part 2 (as below), I examined the company's business fundamentals in more detail along with its growth potential and appropriate valuation...
223 Views
Eubiologics IPO Part 1 - Schedule, Financials & Valuation
Eubiologics is a very "young" vaccine company that develops an oral cholera vaccine product called "Euvichol". This company will be Korea's first...
355 Views
Korea Stock Market Monthly Recap #9 - (December 2016)
The economic hope post Trump win continued to play out in the global equity markets in December. Dow Jones Industrial Average was up 3.3% and...
463 Views
Celltrion Healthcare IPO - Early Review on Key Issues
Celltrion Healthcare, which is Celltrion (068270)’s overseas sales and marketing unit, submitted the application for preliminary screening for...
264 Views
Free Cash Flow Remains King in Weeding Out the Winners and Losers
The Korean Stock Market remains surprisingly fundamental driven and free cash flow remains a fundamental factor that could help investors to weed...
273 Views